AU2023231645A1 - Preventive treatment of migraine - Google Patents
Preventive treatment of migraine Download PDFInfo
- Publication number
- AU2023231645A1 AU2023231645A1 AU2023231645A AU2023231645A AU2023231645A1 AU 2023231645 A1 AU2023231645 A1 AU 2023231645A1 AU 2023231645 A AU2023231645 A AU 2023231645A AU 2023231645 A AU2023231645 A AU 2023231645A AU 2023231645 A1 AU2023231645 A1 AU 2023231645A1
- Authority
- AU
- Australia
- Prior art keywords
- atogepant
- treatment
- migraine
- baseline
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263269105P | 2022-03-09 | 2022-03-09 | |
| US63/269,105 | 2022-03-09 | ||
| US202263347265P | 2022-05-31 | 2022-05-31 | |
| US63/347,265 | 2022-05-31 | ||
| US202263404352P | 2022-09-07 | 2022-09-07 | |
| US63/404,352 | 2022-09-07 | ||
| US202363480365P | 2023-01-18 | 2023-01-18 | |
| US63/480,365 | 2023-01-18 | ||
| PCT/US2023/064027 WO2023173005A2 (en) | 2022-03-09 | 2023-03-09 | Preventive treatment of migraine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023231645A1 true AU2023231645A1 (en) | 2024-09-12 |
Family
ID=87936018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023231645A Pending AU2023231645A1 (en) | 2022-03-09 | 2023-03-09 | Preventive treatment of migraine |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230321055A1 (https=) |
| EP (1) | EP4489856A4 (https=) |
| JP (1) | JP2025508004A (https=) |
| CN (1) | CN119421710A (https=) |
| AU (1) | AU2023231645A1 (https=) |
| CA (1) | CA3244873A1 (https=) |
| MX (1) | MX2024010878A (https=) |
| WO (1) | WO2023173005A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| CN116390712A (zh) | 2020-07-29 | 2023-07-04 | 阿勒根制药国际有限公司 | 治疗偏头痛 |
| CA3206184A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| EP4408418A1 (en) | 2021-09-27 | 2024-08-07 | Allergan Pharmaceuticals International Limited | Combination comprising atogepant for treating migraine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190374520A1 (en) * | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US20210121541A1 (en) * | 2019-07-05 | 2021-04-29 | Allergan Pharmaceuticals International Limited | CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders |
| CN116390712A (zh) * | 2020-07-29 | 2023-07-04 | 阿勒根制药国际有限公司 | 治疗偏头痛 |
-
2023
- 2023-03-09 MX MX2024010878A patent/MX2024010878A/es unknown
- 2023-03-09 CA CA3244873A patent/CA3244873A1/en active Pending
- 2023-03-09 AU AU2023231645A patent/AU2023231645A1/en active Pending
- 2023-03-09 EP EP23767687.9A patent/EP4489856A4/en active Pending
- 2023-03-09 WO PCT/US2023/064027 patent/WO2023173005A2/en not_active Ceased
- 2023-03-09 CN CN202380026078.8A patent/CN119421710A/zh active Pending
- 2023-03-09 US US18/181,228 patent/US20230321055A1/en active Pending
- 2023-03-09 JP JP2024552730A patent/JP2025508004A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230321055A1 (en) | 2023-10-12 |
| JP2025508004A (ja) | 2025-03-21 |
| CN119421710A (zh) | 2025-02-11 |
| CA3244873A1 (en) | 2023-09-14 |
| WO2023173005A2 (en) | 2023-09-14 |
| MX2024010878A (es) | 2024-09-17 |
| WO2023173005A3 (en) | 2023-11-23 |
| EP4489856A4 (en) | 2026-04-15 |
| EP4489856A2 (en) | 2025-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2023173005A2 (en) | Preventive treatment of migraine | |
| CN112437659B (zh) | 用于治疗抑郁症的右美沙芬和安非他酮的组合 | |
| US12090148B2 (en) | Treatment of migraine | |
| JP7480261B2 (ja) | 片頭痛の処置における使用のためのラスミジタンとｃｇｒｐアンタゴニストとの併用療法 | |
| US20250177378A1 (en) | Treatment of depression | |
| US20190247333A1 (en) | Method of reduction in convulsive seizure frequency | |
| Nsaka et al. | Real‐world evidence following a mandatory treatment break after a 1‐year prophylactic treatment with calcitonin gene‐related peptide (pathway) monoclonal antibodies | |
| US20190224186A1 (en) | Treatment of multiple sclerosis with chs-131 | |
| KR20190073385A (ko) | 결정성 양진의 치료법 | |
| JP2024540641A (ja) | 抗ｔｒｅｍ２抗体及びその使用 | |
| TWI494106B (zh) | Ｎ－２－羥基－乙基－六氫吡－ｎ'－２－乙磺酸（ｈｅｐｅｓ）之止痛及反轉髓鞘脫失損傷用途 | |
| US12383545B1 (en) | Treatment of migraine | |
| Kimura et al. | Asenapine versus olanzapine for the treatment of nausea and vomiting in patients with cancer: A retrospective study | |
| Pan et al. | Administration Timing of Amoxicillin Does Not Influence the Efficacy of Vonoprazan‑Amoxicillin Dual Therapy for Helicobacter pylori Eradication | |
| Franco et al. | Disseminated Mycobacterium abscessus Mimicking Sarcoidosis: A Case of Successful Outcomes Against Clinical Expectations | |
| Shah et al. | Zilucoplan: A Novel Strategy for Management of Myasthenia Gravis | |
| CN118900846A (zh) | 抗trem2抗体及其用途 | |
| WO2025054498A1 (en) | Methods of treating hidradenitis suppurativa | |
| Clark | Top 60 most important medications used in an orofacial pain treatment center | |
| HK40074123A (en) | Combination of dextromethorphan and bupropion for treating depression | |
| TW202313017A (zh) | 治療自發性震顫的方法 | |
| HK40100385A (zh) | 用於神经精神病症的抗抑郁剂和右美沙芬的组合 | |
| Krymchantowski | Overview of Upcoming Treatments for Migraine. Too Much Enthusiasm | |
| HK40048114A (en) | Combination of dextromethorphan and bupropion for treating depression | |
| Williamson | The effect of cocaine use on outcomes for the treatment of heroin dependence in Sydney, Australia |